NCT06477094 RFA Using Multi-Tined Electrodes vs.Traditional Electrodes for Lumbar Spondylosis
| NCT ID | NCT06477094 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arkansas |
| Condition | Lumbar Spondylosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-08-09 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2024-08-09 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Spondylosis is an anatomical defect of the small facet joints between the spinal vertebrae often due to load bearing and mechanical wear. It is a major contributor to lower back pain. The current standard of care in patients diagnosed with spondylosis in the lower back is to perform a radiofrequency ablation (RFA) of the lumbar medial branch nerves which carry the pain signals from that region to the brain. RFA accomplishes this by using radio waves transmitted through inserted electrodes. This leads to a temporary lesion or "burn"; stopping the pain signals from being transmitted as as well as changing the pain signals themselves. The electrodes themselves do not heat up but instead cause ions in the surrounding tissue to vibrate and heat up. When performing the procedure at the UAMS pain clinic, one can use the Stryker system with a single electrode end which protrudes out of the cannula or the Stratus Nimbus electrode with two prongs which expand in a "V"; formation along the sides of the cannula. While testing in chicken tissue shows that the latter electrode type produces a larger lesion size, anecdotal evidence suggests that it may lead to longer term pain relief. As such, the choice is currently left up to physician preference as both are FDA approved for use in this condition. This study is trying to assess if the larger lesion size results in a reduction in impairment of activities of daily living due to pain measured by the patient-reported PROMIS (Patient Reported Measurement Information System)-29 questionnaire. The PROMIS-29 is given to all patients who are seen in the UAMS Pain Clinic at initial and follow-up visits. In this study we would like to randomize what electrode and cannula set is used in RFA for patient's who are already going to be receiving the procedure for treatment for their spondylosis. The study team would then compare the PROMIS outcomes between cases that used the Stryker and Stratus Nimbus electrodes at 1,3,6,9 and 12 months. It is hypothesized that the Nimbus electrode will result in a greater reduction and improvement in PROMIS scores for a longer duration than the Stryker electrode.
Eligibility Criteria
Inclusion Criteria: 1. Greater than 18 years of age 2. Presenting with chronic non-radicular lower back pain 3. Failure of conservative treatment such as physical therapy or NSAID usage 4. Diagnosis of lumbar facet mediated lower back pain by a board-certified chronic pain physician via two sets of prognostic lumbar MBBs with 0.5cc of 0.5% bupivacaine with \>80% pain relief Exclusion Criteria: 1. History of known coagulopathy 2. \> 3 American Society of Anesthesiologists Classification 3. Pregnancy 4. Spinal hardware between L3 and S1 5. Allergies to injection medications 6. English illiteracy 7. Pain improvement following physical therapy or NSAID usage 8. Previous history of attempted lumbar RFA
Contact & Investigator
Aparna Jindal, MD
PRINCIPAL INVESTIGATOR
University of Arkansas
Frequently Asked Questions
Who can join the NCT06477094 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lumbar Spondylosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06477094 currently recruiting?
Yes, NCT06477094 is actively recruiting participants. Contact the research team at edenton@uams.edu for enrollment information.
Where is the NCT06477094 trial being conducted?
This trial is being conducted at Little Rock, United States.
Who is sponsoring the NCT06477094 clinical trial?
NCT06477094 is sponsored by University of Arkansas. The principal investigator is Aparna Jindal, MD at University of Arkansas. The trial plans to enroll 25 participants.